Traveler's Disease Vaccine in Trials
GAITHERSBURG, Md - Officials at Antex Biolgics Inc., have announced they will being testing their Activax combination vaccine. Activax reportedly is designed to protect those inoculated from Campylobacter jejuni and Shigella sonnei.
Campylobacter jejuni is estimated to cause 400-500 million causes of diarrhea worldwide annually. The bacterium is found in contaminated food and water. Shigella also causes an additional 200 million cases each year and frequently causes endemic or epidemic dysentery.
Consumption of contaminated food and water are the most prevalent causes of traveler's disease. Symptoms include: gastritis, acute diarrhea, high fever, dehydration, severe dysentery and death.
Patient enrollment at the Naval medical Research Center at the Walter Reed Army Institute of medical Research in Forest Glen, Maryland begins this week.
Point-of-Care Engagement in Long-Term Care Decreasing Infections
November 26th 2024Get Well’s digital patient engagement platform decreases hospital-acquired infection rates by 31%, improves patient education, and fosters involvement in personalized care plans through real-time interaction tools.
Comprehensive Strategies in Wound Care: Insights From Madhavi Ponnapalli, MD
November 22nd 2024Madhavi Ponnapalli, MD, discusses effective wound care strategies, including debridement techniques, offloading modalities, appropriate dressing selection, compression therapy, and nutritional needs for optimal healing outcomes.
The Leapfrog Group and the Positive Effect on Hospital Hand Hygiene
November 21st 2024The Leapfrog Group enhances hospital safety by publicizing hand hygiene performance, improving patient safety outcomes, and significantly reducing health care-associated infections through transparent standards and monitoring initiatives.
